Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Global Blood Therapeutics
Age
45–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented diagnosis of IPF.
Receiving supplemental oxygen for use at rest.
Weight ≥ 40 kg.
Male or female of child bearing potential willing and able to use highly effective methods of contraception from study start to 30 days after the last dose of study drug.
You may not be if
FEV1/FVC \< 70%
History of other interstitial lung diseases.
Subject plans to begin or has commenced pulmonary rehabilitation within 30 days of screening.
Corticosteroid (\> 10 mg per day of prednisone or an equivalent) administered for 7 days or longer, within 30 days of screening.
Participated in another clinical trial of an investigational drug (or medical device) within 30 days or 5-half-lives, whichever is longer, prior to screening, or is currently participating in another trial of an investigational drug (or medical device).
Female who is breast-feeding or pregnant
Current smoker or history of smoking within 3 months from screening
Clareo Health | Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest
